Page last updated: 2024-11-13

acenocoumarol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54676537
CHEMBL ID397420
CHEBI ID53766
SCHEMBL ID1477562
SCHEMBL ID33543
MeSH IDM0000105

Synonyms (137)

Synonym
BRD-A65051990-001-03-8
PRESTWICK2_000110
BSPBIO_000100
4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2h-chromen-2-one
g 23350
neositron
syncumar
syntrom
g-23350
acenocoumarol [inn]
sinkumar
2h-1-benzopyran-2-one, 4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-
sintroma
sincoumar
sinthrom
ascumar
acenokumarin [czech]
acenocumarolum
einecs 205-807-3
sinthrome
g23350
coumarin, 3-(alpha-acetonyl-p-nitrobenzyl)-4-hydroxy-
acenocumarolo [dcit]
acenocumarol
syncoumar
sintrom
g-23,350
zotil
hsdb 3201
acenocoumarolum [inn-latin]
AB-014/25000129 ,
acenocoumarin
acenocoumarol
152-72-7
PRESTWICK_773
NCGC00016414-01
cas-152-72-7
PRESTWICK3_000110
BPBIO1_000110
NCGC00179658-01
mini-sintrom (tn)
acenocoumarol (inn)
D07064
smr000162652
MLS000539171 ,
AB00513804
3-(alpha-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin
3-(alpha-(4'-nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin
nicoumalone
3-(alpha-(p-nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin
3-(alpha-acetonyl-4-nitrobenzyl)-4-hydroxycoumarin
4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2h-1-benzopyran-2-one
nitrowarfarin
3-(alpha-p-nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin
acenocumarolo
nitrophenylacetylethyl-4-hydroxycoumarine
acenokumarin
DB01418
nitrovarfarian
nicumalon
PRESTWICK1_000110
SPBIO_002039
PRESTWICK0_000110
MLS001074461
minisintrom
mini-sintrom
nsc-760052
CHEMBL397420
FT-0660961
FT-0660960
FT-0660959
CHEBI:53766 ,
acenocoumarolum
HMS1568E22
HMS2095E22
SCHEMBL1477562
nsc760052
pharmakon1600-01502411
dtxcid802541
tox21_110430
dtxsid2022541 ,
HMS2232P20
i6wp63u32h ,
trombostop
acitrom
nsc 760052
unii-i6wp63u32h
acenocoumarol [inn:ban:nf]
AKOS015962123
2-acetamido-1,2,5-trideoxy-1,5-imino-d-glucitol
AB07575
AB07577
AB03786
HMS3372J11
3-(.alpha.-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin
acenocoumarol [who-dd]
acenocoumarol [mi]
acenocoumarol [hsdb]
acenocoumarol [mart.]
CCG-213077
AB00527557-09
SCHEMBL33543
NCGC00179658-04
tox21_110430_1
CS-4527
W-108047
2h-1-benzopyran-2-one, 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-
4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2h-chromen-2-one #
3-(.alpha.-(4-nitrophenyl)-.beta.-acetylethyl)-4-hydroxycoumarin
3-(.alpha.-(p-nitrophenol)-.beta.-acetylethyl)-4-hydroxycoumarin
3-(.alpha.-p-nitrophenyl-.beta.-acetylethyl)-4-hydroxycoumarin
3-(.alpha.-acetonyl-4-nitrobenzyl)-4-hydroxycoumarin
VABCILAOYCMVPS-UHFFFAOYSA-N
3-(.alpha.-acetonyl-p-nitrophenyl)-4-hydroxycoumarin
3-(.alpha.-acetonyl-p-nitrobenzyl)-4-hydroxy-coumarin
coumarin, 3-(.alpha.-acetonyl-p-nitrobenzyl)-4-hydroxy-
HY-B1014
AB00513804_02
OPERA_ID_1500
4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-2-one
gtpl9015
mfcd00137816
3-(alpha-acetonyl-p-nitrobenzyl)-4-hydroxy-coumarin
(+/-)-acenocoumarin
SR-01000678252-3
sr-01000678252
acenocoumarol, united states pharmacopeia (usp) reference standard
T70324
acenocoumarol, >=98% (hplc)
HMS3713F17
Q304088
3-(a-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin
4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2h-chromen-2-one
2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-1-benzopyran-4-one
DTXSID00991186
AS-56473
EN300-18472689

Research Excerpts

Overview

Achenocoumarol (Sintrom®) is an oral anticoagulant prescribed for the treatment of a variety of thromboembolic disorders such as atrial fibrillation and thrombosis or embolism. It is a vitamin-K antagonist (VKA) primarily used in certain countries.

ExcerptReferenceRelevance
"Acenocoumarol is an oral anticoagulant with a narrow therapeutic range."( Biomodification of acenocoumarol by bifidobacteria.
Assad, S; Fragomeno, M; Minnaard, J; Mobili, P; Pérez, PF; Peruzzo, PJ, 2021
)
1.67
"Acenocoumarol is an anticoagulant with numerous drug reactions. "( Azathioprine and Acenocoumarol Drug Interaction in Patients with Crohn's Disease: A Case Report.
Belhadj, A; Ben-Hammamia, S; Bouchrika, A; Charfi, O; Chebbi, F; El Aidli, S; Lakhoua, G, 2023
)
2.69
"Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. "( Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain.
Arenillas, J; Besora, S; Buongiorno, MT; Cabezas, JA; Calleja, A; Cambray, S; Camps-Renom, P; Cárcel-Márquez, J; Carrera, C; Castillo, J; Cullell, N; de Torres-Chacón, R; Fernández-Cádenas, I; Font, MÀ; Freijo, MDM; Gallego-Fabrega, C; Giralt-Steinhauer, E; González-Sánchez, J; Hernandez-Perez, M; Jiménez-Conde, J; Krupinski, J; López-Cancio, E; Mancha, F; Martí-Fàbregas, J; Molina, J; Montaner, J; Muiño, E; Obach, V; Prats-Sánchez, L; Purroy, F; Rodríguez-Yáñez, M; Sobrino, T; Sotoca, J; Torres-Aguila, NP; Tur, S; Vives-Bauzá, C, 2020
)
2.25
"Acenocoumarol is a vitamin-K antagonist (VKA) primarily used in certain countries (e.g. "( Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study.
García-Sempere, A; Hurtado, I; Peiró, S; Rodríguez-Bernal, CL; Sanfélix-Gimeno, G; Santa-Ana-Téllez, Y, 2021
)
2.31
"Acenocoumarol is an oral anticoagulant medicinal agent is frequently prescribed for the prophylaxis and the management of thromboembolic events. "( A Brief Review on Determination of Acenocoumarol in Biological and Pharmaceutical Specimens: Analytical Methodologies.
Chaudhari, SR; Mhaske, PD; Shirkhedkar, AA, 2022
)
2.44
"Acenocoumarol (Sintrom®) is an oral anticoagulant prescribed for the treatment of a variety of thromboembolic disorders such as atrial fibrillation and thrombosis or embolism. "( Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma.
Estevez, MC; Lechuga, LM; Marco, MP; Peláez, EC; Portela, A; Salvador, JP, 2018
)
2.17
"Acenocoumarol is a vitamin K antagonist used in some European countries. "( P-glycoprotein: a clue to vitamin K antagonist stabilization.
Boehlen, F; Bonnabry, P; Combescure, C; Dayer, P; Desmeules, JA; Gschwind, L; Matthey, A; Rebsamen, M; Rollason, V, 2015
)
1.86
"Acenocoumarol (AC) is a vitamin K antagonist used in anticoagulant therapy and as a prophylaxis measure in Europe."( The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation.
Ananichuk, AV; Kazakov, RE; Rozhkov, AV; Sychev, DA, 2016
)
1.38
"Acenocoumarol is a vitamin K antagonist that is used for the treatment of acquired and congenital, both arterial and venous, thrombotic diseases. "( Surgical management of severe spontaneous hemorrhage of the abdominal wall complicating acenocoumarol treatment.
Chatzopoulos, S; Ioannidis, O; Kakoutis, E; Konstantara, A; Kotronis, A; Makrantonakis, A; Papadimitriou, N; Paraskevas, G, 2012
)
2.04
"Acenocoumarol is a commonly prescribed anticoagulant drug for the prophylaxis and treatment of venous and arterial thromboembolic disorders in several countries. "( Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Antón, AI; Cerezo-Manchado, JJ; Corral, J; Garcia-Barberá, N; González-Conejero, R; Martinez, AB; Pérez-Andreu, V; Roldán, V; Rosafalco, M; Vicente, V, 2013
)
2.09
"Acenocoumarol (AC) is a coumarin derivative, vitamin K antagonist anticoagulant drug. "( Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
Doncheva, E; Eap, CB; Ganev, VS; Paskaleva, ID; Saraeva, RB, 2007
)
2.11

Effects

Achenocoumarol has a narrow therapeutic range, and its effects depend on several factors, such as body weight, age, metabolism, diet, certain medical conditions or the intake of additional drugs, among others.

Acenocoumarol use has been reported to be associated with two-fold higher risk for instability of anticoagulation control compared to warfarin administration.

ExcerptReferenceRelevance
"Acenocoumarol has a narrow therapeutic range, and its effects depend on several factors, such as body weight, age, metabolism, diet, certain medical conditions or the intake of additional drugs, among others."( Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma.
Estevez, MC; Lechuga, LM; Marco, MP; Peláez, EC; Portela, A; Salvador, JP, 2018
)
1.45
"Acenocoumarol (ACN) has a narrow therapeutic range that is especially difficult to control at the start of its administration. "( Extrapolation of acenocoumarol pharmacogenetic algorithms.
Calleja-Hernández, MÁ; Cañadas-Garre, M; Garcés-Robles, V; Gutiérrez-Pimentel, MJ; Jiménez-Varo, E, 2015
)
2.2
"Acenocoumarol use has been reported to be associated with two-fold higher risk for instability of anticoagulation control compared to warfarin administration."( Switching from acenocoumarol to warfarin in patients with unstable anticoagulation and its effect on anticoagulation control.
Cieśla-Dul, M; Tracz, W; Undas, A; Zółciński, M, 2009
)
1.43
"Acenocoumarol has been proposed repeatedly as a safe alternative drug regimen for oral anticoagulation in patients who have suffered phenprocoumon-induced fulminant hepatic failure. "( Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases.
Fischer, HP; Kerekes, Z; Neef, M; Sauerbruch, T; Spengler, U, 2003
)
3.2
"Acenocoumarol might not have been the initiating factor of delayed hemothorax, but could be blamed for the exacerbation of bleeding."( Delayed 31st day traumatic hemothorax on acenocoumarol for aortic valve replacement.
Avgerinos, ED; Papalampros, A; Perdikides, T; Siafakas, KX, 2008
)
1.33

Treatment

Akenocoumarol was found to speed recovery of ischemia/reperfusion-induced acute pancreatitis in rats. Treatment with acenocou marol alone, according to the hypothesis that high dosages of oral anticoagulants obviate the need for heparin, is considered an effective alternative in some countries.

ExcerptReferenceRelevance
"476 acenocoumarol-treated CVT patients (153 males and 323 females) were genotyped for CYP2C9*2 and CYP2C9*3 polymorphisms by PCR-RFLP method. "( Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
Christopher, R; De, T; Nagaraja, D, 2014
)
1.2
"acenocoumarol in patients treated in Chile's public health system."( Latin American Clinical Epidemiology Network Series - Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile.
Bustos, L; Castro, C; de La Puente, C; Lanas, F; Vallejos, C; Velasquez, M; Zaror, C, 2017
)
1.4
"The acenocoumarol treatment was withheld and the skin lesions resolved spontaneously over the next 10 days."( Acenocoumarol and vasculitis: a case report.
Amri, M; Aouam, K; Bel Hadj Ali, H; Boughattas, NA; Gassab, A; Khorchani, H; Zili, JE, 2007
)
2.26
"Acenocoumarol treatment did not result in a significant reduction of acute vasoocclusive events (three painful crises during acenocoumarol, five painful crises during placebo)."( Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study.
Brandjes, DP; Duits, AJ; Kater, AP; Lard, LR; Mac Gillavry, MR; Rojer, RA; Schnog, JB; ten Cate, H; van Der Dijs, FP; van Eps, LW, 2001
)
1.37
"Treatment with acenocoumarol accelerates the recovery of ischemia/reperfusion-induced acute pancreatitis in rats."( Therapeutic Effect of Low Doses of Acenocoumarol in the Course of Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats.
Ambroży, T; Bonior, J; Ceranowicz, P; Cieszkowski, J; Dembiński, A; Dembiński, M; Jaworek, J; Kuśnierz-Cabala, B; Olszanecki, R; Sendur, P; Sendur, R; Tomasz, K; Tomaszewska, R; Warzecha, Z, 2017
)
1.09
"Pretreatment with acenocoumarol given at the dose of 50 or 100 μg/kg/dose reduced morphological signs of acute pancreatitis."( Pretreatment with low doses of acenocoumarol inhibits the development of acute ischemia/reperfusion-induced pancreatitis.
Ceranowicz, P; Cieszkowski, J; Dembinski, A; Dembinski, M; Kusnierz-Cabala, B; Sendur, P; Tomaszewska, R; Warzecha, Z, 2015
)
1.03
"Treatment with acenocoumarol alone, according to the hypothesis that high dosages of oral anticoagulants obviate the need for heparin, is considered an effective alternative in some countries."( Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.
Brandjes, DP; Büller, HR; de Rijk, M; Heijboer, H; Jagt, H; ten Cate, JW, 1992
)
2.07

Toxicity

Acenocoumarol has been proposed as a safe alternative drug regimen for oral anticoagulation in patients who have suffered phenprocoumon-induced fulminant hepatic failure.

ExcerptReferenceRelevance
"To determine the incidence of adverse effects of antithrombotic drugs (platelet anti-aggregants and anticoagulants) in patients with transient ischemic attacks (TIA) and mild ischemic strokes (IL)."( [Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease].
Cabezas, C; Clavería, LE; Duarte, J; Ferrero, M; Guerrero, P; Sempere, AP; Tabernero, C; Tahoces, ML,
)
0.13
" Adverse effects which led to suspension of treatment or were a potential danger for the patient's life were recorded."( [Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease].
Cabezas, C; Clavería, LE; Duarte, J; Ferrero, M; Guerrero, P; Sempere, AP; Tabernero, C; Tahoces, ML,
)
0.13
" Adverse effects led to suspension of treatment in 6% (5% with aspirin and acenocumarol, 17% with ticlopidine)."( [Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease].
Cabezas, C; Clavería, LE; Duarte, J; Ferrero, M; Guerrero, P; Sempere, AP; Tabernero, C; Tahoces, ML,
)
0.13
"Acenocoumarol has been proposed repeatedly as a safe alternative drug regimen for oral anticoagulation in patients who have suffered phenprocoumon-induced fulminant hepatic failure."( Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases.
Fischer, HP; Kerekes, Z; Neef, M; Sauerbruch, T; Spengler, U, 2003
)
3.2
" No differences between the groups were detected concerning demographic or basal characteristics in clinical evolution or adverse reactions."( A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis.
Cirujeda, JL; Granado, PC,
)
0.36
" The transradial approach appears to be a safe option for patients receiving long-term coumarin treatment and could be the technique of choice because it avoids the drawbacks and complications associated with the withdrawal of oral anticoagulation."( [Safety of diagnostic transradial catheterization in patients undergoing long-term anticoagulation with coumarin derivatives].
Baz, JA; Hervert, F; Iñiguez, A; Pereira, B; Rúa, R; Sanmartín, M; Vázquez, S, 2007
)
0.34
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Outpatient implantation of implantable cardioverter-defibrillators is safe and reduces costs."( Safety of Outpatient Implantation of the Implantable Cardioverter-defibrillator.
Arenal Maíz, Á; Atienza Fernández, F; Ávila Alonso, P; Datino, T; Eidelman, G; Fernández-Avilés, F; González-Torrecilla, E; Hernández-Hernández, J; Miracle Blanco, Á; Núñez García, A, 2015
)
0.42
" Acenocoumarol is effective and safe in all age groups."( Acenocoumarol: A Review of Anticoagulant Efficacy and Safety.
Hiremath, JS; Kanhere, V; Mishra, YK; Sawhney, J; Srinivasa, R; Tiwaskar, M; Trailokya, A, 2016
)
2.79

Pharmacokinetics

Aliskiren has no clinically relevant effect on the pharmacokinetics or pharmacodynamic effects of a single dose of acenocoumarol in healthy volunteers. No dosage adjustment is likely to be required during co-administration with aliskiren.

ExcerptReferenceRelevance
" The results show that pharmacokinetic constants obtained in the anaesthetized animal may differ greatly from those in the conscious one."( The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat.
Daemen, MJ; Smits, JF; Struyker Boudier, HA; Thijssen, HH; Vervoort-Peters, HT, 1986
)
0.48
" We investigated the steady-state pharmacokinetic disposition of S-acenocoumarol in plasma, liver, testis, and kidney following its administration (constant rate infusion by an osmotic minipump) directly into the testis or the kidney of rats."( Pharmacokinetic evaluation of local drug delivery: the intratesticular and intrarenal administration of acenocoumarol in the rat.
Daemen, MJ; Thijssen, HH; Vervoort-Peters, HT, 1988
)
0.73
" 4 The apparent elimination half-life of S(-) was much shorter than those of R(+) and the racemate, which were similar."( Pharmacokinetics of the enantiomers of acenocoumarol in man.
Gerardin, A; Godbillon, J; Jähnchen, E; Kasper, W; Meinertz, T; Richard, J, 1981
)
0.53
" The pharmacokinetic and pharmacodynamic interactions of warfarin during co-treatment with Danshen extract observed in this study indicate an explanation for the clinically observed incidents of exaggerated warfarin adverse effects when traditional Chinese medicinal herbs or herbal products such as Danshen and Danggui (observed in a previous study) were co-administered."( The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats.
Chan, K; Lo, AC; Woo, KS; Yeung, JH, 1995
)
0.29
" On day 2 of each study period, a single 10 mg oral dose of racemic acenocoumarol was administered and venous blood samples were collected for pharmacokinetic and pharmacodynamic assessments."( No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics.
Beysens, AJ; de Hoon, JN; Thijssen, HH; Van Bortel, LM, 1997
)
0.79
" In spite of the short pharmacokinetic half-life of acenocoumarol, a stable nycthemeral pharmacodynamic activity was observed after once daily administration; twice-daily administration of acenocoumarol does not appear to be justified."( Pharmacokinetic and pharmacodynamic variations of acenocoumarol orally administrated either once or twice daily in patients with deep venous thrombosis.
Buchmuller, A; Decousus, H; Laporte-Simitsidis, S; Mismetti, P; Reynaud, J; Tardy, B; Tardy-Poncet, B; Thijssen, H, 1998
)
0.8
" An approach to predict pharmacokinetic interactions of lornoxicam from in vitro inhibition data was developed."( Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
Kohl, C; Steinkellner, M, 2000
)
0.31
"The pharmacokinetics of S -acenocoumarol in this subject differed greatly (oral clearance, 6%-10%; half-life of elimination, 400%-500%) from the values of a [wt/wt] control and from population values."( Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
de Vries-Hanje, JC; Drittij, MJ; Thijssen, HH; Vervoort, LM, 2001
)
0.88
"To evaluate pharmacokinetic and pharmacodynamic interactions between tamsulosin and acenocoumarol."( A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol.
Clarke, C; Mullins, F; Rolan, P; Terpstra, IJ; Visser, JN, 2003
)
0.76
"A study was carried out to evaluate the potential pharmacokinetic interaction between digoxin and acenocoumarol."( Pharmacokinetic study of the digoxin-acenocoumarol interaction in rabbits.
Alberca, I; Atencio, DR; Lanao, JM; Lopez, FG; Martin-Suarez, A; Mendez, ME; Santos, M; Zarzuelo, A, 2003
)
0.81
" Pharmacokinetic parameters of acenocoumarol were calculated by noncompartmental analysis and revealed that in both patients the area under the concentration-time curve up to 24 h after the acenocoumarol administration was higher following E7070 (2."( Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
Beijnen, JH; Critchley, DJ; Schellens, JH; Sparidans, RW; van den Bongard, HJ, 2004
)
0.84
" The pharmacokinetic and pharmacodynamic parameters of acenocoumarol were determined by noncompartmental analysis."( The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Bigler, H; Ligueros-Saylan, M; McLeod, J; Prasad, P; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.8
"The aim of this study was to investigate the respective contribution of the different cytochrome P450 (CYP) 2C9 genetic polymorphisms to the interindividual variability of acenocoumarol pharmacodynamic response."( Pharmacogenetics of acenocoumarol pharmacodynamics.
Beaune, PH; Becquemont, L; Bodin, L; Dubert, L; Funck-Brentano, C; Jaillon, P; Laurent-Puig, P; Loriot, MA; Morin, S; Robert, A; Strabach, S; Thijssen, HH; Tregouet, DA; Verstuyft, C, 2004
)
0.84
" Body weight explained 5% of acenocoumarol pharmacodynamic variability, whereas the NQO1*2 allele had no significant effect."( Pharmacogenetics of acenocoumarol pharmacodynamics.
Beaune, PH; Becquemont, L; Bodin, L; Dubert, L; Funck-Brentano, C; Jaillon, P; Laurent-Puig, P; Loriot, MA; Morin, S; Robert, A; Strabach, S; Thijssen, HH; Tregouet, DA; Verstuyft, C, 2004
)
0.94
"Overall, CYP2C9-related genetic variability accounts for 14% of the interindividual variability in acenocoumarol pharmacodynamic response."( Pharmacogenetics of acenocoumarol pharmacodynamics.
Beaune, PH; Becquemont, L; Bodin, L; Dubert, L; Funck-Brentano, C; Jaillon, P; Laurent-Puig, P; Loriot, MA; Morin, S; Robert, A; Strabach, S; Thijssen, HH; Tregouet, DA; Verstuyft, C, 2004
)
0.86
" These large dose response variations are markedly influenced by pharmacokinetic aspects that are determined by genetic, environmental and possibly other yet unknown factors."( Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer, M, 2005
)
0.55
"Aliskiren has no clinically relevant effect on the pharmacokinetics or pharmacodynamic effects of a single dose of acenocoumarol in healthy volunteers, hence no dosage adjustment of acenocoumarol is likely to be required during co-administration with aliskiren."( Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
Bizot, MN; Dieterich, HA; Dole, WP; Howard, D; Huang, HL; Vaidyanathan, S; Yeh, CM, 2008
)
0.76
" The results indicated that pharmacodynamic response to acenocoumarol is highly variable between the subjects."( Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.
Allabi, AC; Alvarez, JC; Bigot, A; Gala, JL; Horsmans, Y; Verbeeck, RK; Yasar, U, 2012
)
2.07
" The pharmacodynamic response was best described by an indirect action model with S-acenocoumarol concentrations and fluindione concentrations as the only exposure predictors of the INR response."( A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Becquemont, L; Delavenne, X; Diquet, B; Jaillon, P; Lebot, M; Robert, A; Rousseau, A; Tod, M; Verstuyft, C, 2012
)
0.81

Compound-Compound Interactions

The aim of this study was to describe a potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease. These results indicate that E7070 ma may have a positive effect on blood vessel function. Most analyzed drugs interact with acenoparol via a pharmacokinetic mechanism.

ExcerptReferenceRelevance
" Nine healthy volunteers received three treatments: 1) 10 mg acenocoumarol in combination with cimetidine, 2) 10 mg acenocoumarol in combination with placebo, 3) 10 mg acenocoumarol after one week pretreatment with pentobarbitone."( Detection of drug interactions with single dose acenocoumarol: new screening method?
Cohen, AF; de Boer, A; Edelbroek, PM; Hoogkamer, JF; Kroon, C; Schoemaker, HC; van der Meer, EJ, 1990
)
0.78
" These results indicate that E7070 may primarily interact with acenocoumarol by reducing its systemic clearance."( Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
Beijnen, JH; Critchley, DJ; Schellens, JH; Sparidans, RW; van den Bongard, HJ, 2004
)
0.79
" Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione."( Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Andrus, MR, 2004
)
0.32
"The aim of this study was to describe a potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease."( Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease.
Camarda, C; Camarda, R; Monastero, R, 2007
)
0.81
"This case report suggests a possible drug-drug interaction between duloxetine and acenocoumarol."( Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease.
Camarda, C; Camarda, R; Monastero, R, 2007
)
0.81
"A pharmacokinetic-pharmacodynamic (PK-PD) drug-drug interaction between acenocoumarol and amoxicillin + clavulanic acid antibiotic was assessed in eight healthy volunteers, using a population PK-PD) model."( Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
Basset, T; Delavenne, X; Demasles, S; Girard, P; Laporte, S; Mallouk, N; Mismetti, P; Tod, M, 2009
)
0.83
"The objective of this study was to identify the most clinically relevant drug-drug interactions (DDIs) at risk of affecting acenocoumarol safety in our tertiary care university hospital, a 2,000 bed institution."( Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.
Boehlen, F; Bonnabry, P; Dayer, P; Desmeules, JA; Gschwind, L; Lovis, C; Rollason, V, 2013
)
0.82
" Most analyzed drugs interact with acenocoumarol via a pharmacokinetic mechanism."( Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.
Boehlen, F; Bonnabry, P; Dayer, P; Desmeules, JA; Gschwind, L; Lovis, C; Rollason, V, 2013
)
0.89
"The objective of this study was to investigate the impact of CYP2C9 polymorphisms and drug-drug interactions on the risk of overanticoagulation in patients treated with acenocoumarol, a vitamin K antagonist."( Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
Boehlen, F; Bonnabry, P; Combescure, C; Dayer, P; Desmeules, JA; Grünenwald, M; Gschwind, L; Matthey, A; Rebsamen, M; Rollason, V, 2013
)
0.8
"01) in the presence of a clinically significant drug-drug interaction."( Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
Boehlen, F; Bonnabry, P; Combescure, C; Dayer, P; Desmeules, JA; Grünenwald, M; Gschwind, L; Matthey, A; Rebsamen, M; Rollason, V, 2013
)
0.61
"These findings support the fact that CYP2C9 genotyping could be useful to identify patients requiring closer monitoring, especially when a drug-drug interaction is expected."( Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
Boehlen, F; Bonnabry, P; Combescure, C; Dayer, P; Desmeules, JA; Grünenwald, M; Gschwind, L; Matthey, A; Rebsamen, M; Rollason, V, 2013
)
0.61
"The aims of this study are to evaluate prevalence and characteristics of adverse drug reactions (ADRs) and to evaluate the potential contribution of specific medications, therapeutic categories and drug-drug interactions (DDIs) in older adults."( Understanding adverse drug reactions in older adults through drug-drug interactions.
Bettoni, D; Brognoli, F; Concoreggi, C; Marengoni, A; Martini, G; Nobili, A; Onder, G; Pasina, L, 2014
)
0.4
"In AF patients, the risk of bleeding is higher when antiplatelet therapy is combined with acenocoumarol, but the risk of mortality and stroke was not significantly different from that of patients taking only acenocoumarol."( Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality.
Esteve-Pastor, MA; Lip, GYH; Marín, F; Rivera-Caravaca, JM; Roldán, V; Valdés, M; Vicente, V, 2018
)
0.98

Bioavailability

ExcerptReferenceRelevance
" The results indicate that Danshen extracts can increase the absorption rate constant, area under plasma concentration-time curves, maximum concentrations and elimination half-lives, but decreases the clearances and apparent volume of distribution of both R- and S-warfarin."( The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats.
Chan, K; Lo, AC; Woo, KS; Yeung, JH, 1995
)
0.29
"The aim of this study was to compare the bioavailability of an oral formulation of the coumarin derivative-vitamine K antagonist acenocoumarol (Acebron™ 4 mg, Test) with the reference formulation (Neo-Sintrom™ 4 mg)."( Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations.
Cáceres, D; Carmona, P; Ortiz, M; Quiñones, L; Saavedra, I; Sasso, J; Tamayo, E; Varela, N, 2012
)
0.92
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

In 9 trials, 2812 patients were randomized to receive warfarin, acenocoumarol, or phenprocoumon according to a genotype-guided algorithm or a clinical dosing algorithm. In the in vivo study, the kinetics of digoxin administered in single and multiple dosage regimens were compared.

ExcerptRelevanceReference
" After 2 years of this therapy he developed periarthritis of the right shoulder, followed suddenly by hemarthrosis of the right shoulder which remained symptomatic for 9 months in spite of several joint aspirations and reduction in the dosage of heparin administered during hemodialysis."( [Hemarthroses complicating anticoagulant therapy (heparin, oral anticoagulants)].
Gerster, JC; Saudan, Y; Waldburger, M; Wauters, JP, 1977
)
0.26
" In such patients the prothrombin ratio should be closely monitored and the anticoagulant dosage adjusted accordingly."( Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration.
Caraco, Y; Rubinow, A, 1992
)
0.28
"The blood coagulating factors II and VII and prothrombin times (Thrombotest) were followed during a dosage interval (= 24 h) in patients on acenocoumarol (n = 6) and on phenprocoumon (n = 6) therapy."( 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship.
Hamulyák, K; Thijssen, HH; Willigers, H, 1988
)
0.48
" Side-effects of ticlopidine were rare and patient management with the standard dosage of this drug was easier than oral anticoagulation."( Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
Goebel, N; Krayenbühl, HP; Pfluger, N; Rothlin, ME; Senning, A; Speiser, K; Steinbrunn, W; Turina, M, 1985
)
0.27
" Apparent failures of this treatment may be caused by insufficient information on the part of either the physician or the patient himself, poor standardization of laboratory tests and/or inadequate dosage of vitamin K antagonists."( [How can we improve long-term anticoagulation?].
Beck, EA, 1985
)
0.27
" It is concluded that when initiating and withdrawing treatment with SP in a patient receiving AC, the prothrombin time should be checked daily for a few days to adapt (reduce) the dosage of AC to the change in prothrombin time induced by SP."( [The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol].
Fontanilles, F; Holt, NF; Michot, F, 1981
)
0.5
" While not warranting the routine use of the chromogenic assay for factor VII in place of the prothrombin time using BCT, the factor VII amidolytic assay offers a limited but dependable guide to dosage in long-term patients."( An assessment of an amidolytic assay for factor VII in the laboratory control of oral anticoagulants.
Bodzenta, A; Chmielewska, J; Easton, AC; Latallo, ZS; Poller, L; Thomson, JM, 1981
)
0.26
"Forty-three patients who received acenocoumarol, had stable levels of International Normalized Ratio (INR), and did not need dosage modification for four months before entering the study."( Lack of effect of influenza vaccine on anticoagulation by acenocoumarol.
Fontcuberta, J; Mateo, J; Montserrat, I; Oliver, A; Souto, JC; Sureda, A, 1993
)
0.81
" The model will be used to better define the dosage regimen for future clinical developments."( Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol.
Boissel, JP; Dechavanne, M; Delair, S; Erhardtsen, E; Ffrench, P; Girard, P; Nony, P, 1998
)
0.52
" To test this hypothesis this study compared the dosing of acenocoumarol in orthopedic and surgical patients using an algorithm with routine dosing."( Initiation of oral anticoagulant therapy in orthopedic and surgical patients: an algorithm compared with routine dosing.
Baars, WA; Beinema, M; Brouwers, JR; Mencke, HJ; Sijtsma, J; van den Bemt, PM; van Roon, EN, 2002
)
0.56
"The retrospective analysis of data (age, body weight, international normalized ratio, loading and maintenance doses, time to achieve the steady state) led to the building of a dosage nomogram usable in pediatrics."( [Acenocoumarol (Sintrom) and fluinidione (Previscan) in pediatrics after cardiac surgical procedures].
Doubine, S; Losay, J; Piquet, P, 2002
)
1.22
" In the in vivo study, the kinetics of digoxin administered in single and multiple dosage regimens were compared in control rabbits and in rabbits treated simultaneously with acenocoumarol."( Pharmacokinetic study of the digoxin-acenocoumarol interaction in rabbits.
Alberca, I; Atencio, DR; Lanao, JM; Lopez, FG; Martin-Suarez, A; Mendez, ME; Santos, M; Zarzuelo, A, 2003
)
0.79
" This retrospective cohort study compiled data during a three-year period from a computerised dosing and management system."( Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
Antheunissen-Anneveld, I; Breukink-Engbers, WG; de Vries-Goldschmeding, H; Fihn, SD; Gadisseur, AA; Geven-Boere, LM; Harderman, D; Pasterkamp, E; Rosendaal, FR; Smink, M; van der Meer, FJ; van Meegen, E; van't Hoff, AR, 2003
)
0.55
" Our results validate the computerised acenocoumarol dosing in our centre, achieving at least similar levels of effectiveness and safety compared with traditional dosage by medical staff."( A prospective controlled study of a computer-assisted acenocoumarol dosage program.
Bermúdez, A; Fernández-Fontecha, E; López-Duarte, M; Marco, F; Sedano, C; Zubizarreta, A,
)
0.65
" We also determined the role of cytochrome P450 2C9 (CYP2C9) polymorphism on coumarin dosage and INR in NSAID users."( Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
Brouwers, JR; de Jong-van den Berg, LT; de Vries-Bots, AM; Piersma-Wichers, M; Plat, AW; Slomp, J; van Dijk, AA; van Dijk, KN, 2004
)
0.61
"This retrospective study was performed to develop a model to predict the maintenance dosage of the vitamin K antagonist acenocoumarol, based upon the first INR after a standard initial dosage regimen."( Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.
Hutten, BA; Levi, MM; Sturk, A; van Geest-Daalderop, JH, 2003
)
0.76
" The maintenance dosage of the period 3-6 months after the installment was related to the first INR after those standard initial dosage regimens, because in that period the INR was 76% of the time within the therapeutic range and therefore considered suitable to perform the analysis."( Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.
Hutten, BA; Levi, MM; Sturk, A; van Geest-Daalderop, JH, 2003
)
0.55
"A clear relation was found between the first INR, the maintenance dosage and the age."( Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.
Hutten, BA; Levi, MM; Sturk, A; van Geest-Daalderop, JH, 2003
)
0.55
"We have developed a formula to predict the maintenance dosage of acenocoumarol."( Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.
Hutten, BA; Levi, MM; Sturk, A; van Geest-Daalderop, JH, 2003
)
0.79
" This suggests that no dosage adjustments will be required when nateglinide and acenocoumarol are coadministered in clinical practice."( The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Bigler, H; Ligueros-Saylan, M; McLeod, J; Prasad, P; Smith, H; Sunkara, G; Wang, Y, 2004
)
0.78
"A 67-year-old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio (INR) without bleeding when his atorvastatin therapy was switched to fluvastatin."( Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Andrus, MR, 2004
)
0.32
"0 microg/kg/min ARG (days 1, 3, 4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3)."( Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Breddin, HK; Graff, J; Harder, S; Klinkhardt, U; Osakabe, M; von Hentig, N; Walenga, JM; Watanabe, H, 2004
)
0.56
" These algorithms are usually based on an empiric relationship between dosage and International Normalized Ratio and do not quantify the delaying effect of the drug's pharmacokinetics or the effect of alternating doses that are used to approximate a certain average dosage."( A model-based algorithm for the monitoring of long-term anticoagulation therapy.
Kruithof, CJ; Pasterkamp, E; Rosendaal, FR; Van der Meer, FJ; Vanderschoot, JP, 2005
)
0.33
" The use of vitamin K antagonists is complicated by a narrow therapeutic index and an unpredictable dose-response relationship, giving rise to frequent bleeding complications or insufficient anticoagulation."( Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer, M, 2005
)
0.55
"This study was carried out to study the safety and efficacy of a fixed dosage of sulodexide compared to adjusted dosages (INR) of acenocoumarol as secondary prophylaxis in patients with deep vein thrombosis (DVT) in lower limbs."( A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis.
Cirujeda, JL; Granado, PC,
)
0.57
" The impact of these variations in dosage over the stability of anticoagulation is unknown."( Patients who take uneven doses of acenocoumarol exhibit significant fluctuating levels of anticoagulation.
de Heredia, JM; de Zárate, IO; Gutiérrez, JI; Marco, F; Márquez, JA; Ojínaga, MJ; Orkolaga, K, 2006
)
0.61
" The desired level of anticoagulation was achieved with a high dosage of phenprocoumon (18-21 mg daily)."( [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
Touw, DJ; van Meegen, E; Veldkamp, RF; Wilms, EB, 2006
)
0.64
"Aliskiren has no clinically relevant effect on the pharmacokinetics or pharmacodynamic effects of a single dose of acenocoumarol in healthy volunteers, hence no dosage adjustment of acenocoumarol is likely to be required during co-administration with aliskiren."( Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
Bizot, MN; Dieterich, HA; Dole, WP; Howard, D; Huang, HL; Vaidyanathan, S; Yeh, CM, 2008
)
0.76
" The management of oral anticoagulation is challenging because of a large variability in the dose-response relationship, which is in part caused by genetic polymorphisms."( Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Fuhr, U; Kirchheiner, J; Lazar, A; Stehle, S, 2008
)
0.35
" Several warfarin dosing algorithms have been constructed, adapted on CYP2C9 and VKORC1 genotypes and clinical factors, to predict the best dose for each patient."( Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.
Becquemont, L, 2008
)
0.35
"To meet growing demand for oral anticoagulation worldwide there has been increased dependence on computer-assistance in dosage although the safety and effectiveness of any of the individual computer-assisted dosage programs has not previously been established."( A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage.
Ibrahim, S; Jespersen, J; Keown, M; Lowe, G; Moia, M; Palareti, G; Poller, L; Roberts, C; Tripodi, A; Turpie, AG; van den Besselaar, AM; van der Meer, FJ, 2008
)
0.35
" In a multivariable regression model, CYP2C9, VKORC1 genotypes and age explained 55% of acenocoumarol dosing variability."( VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Gialeraki, A; Grouzi, E; Markatos, CN; Merkouri, E; Panagou, I; Politou, M; Spiliotopoulou, I; Travlou, A, 2008
)
0.83
" Other hereditary and nongenetic parameters must be incorporated in an individualized dosing algorithm to achieve a safer anticoagulant effect."( VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Gialeraki, A; Grouzi, E; Markatos, CN; Merkouri, E; Panagou, I; Politou, M; Spiliotopoulou, I; Travlou, A, 2008
)
0.61
" After initial LMWH, patients received 6 months of treatment with full therapeutic dosage of tinzaparin or acenocoumarol."( A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.
Bonell, A; Cairols, MA; Colomé, E; Lapiedra, O; Martí, X; Romera, A; Vila-Coll, R, 2009
)
0.57
" The first international normalized ratio (INR) after initial standard dose, risk of overanticoagulation, and mean dosage at the end of the initiation period were compared between genotypes."( Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
de Smet, PA; Hofman, A; Stricker, BH; Teichert, M; Uitterlinden, AG; van Schaik, RH; Visser, LE, 2009
)
0.57
"Low-molecular-weight heparins are effective as initial therapy for pulmonary embolism (PE) in a weight-based dosing regimen up to known body weights of 160 kg."( Treatment of pulmonary embolism in an extremely obese patient.
Diepstraten, J; Hackeng, CM; Knibbe, CA; Snijder, RJ; van Kralingen, S; van Ramshorst, B, 2009
)
0.35
" We aimed to confirm known or identify new genetic variants contributing to interindividual variation on stabilized acenocoumarol dosage by a GWAS."( A genome-wide association study of acenocoumarol maintenance dosage.
De Smet, PA; Eijgelsheim, M; Hofman, A; Rivadeneira, F; Stricker, BH; Teichert, M; Uitterlinden, AG; van Gelder, T; van Schaik, RH; Visser, LE, 2009
)
0.84
"-1639G > A polymorphism on the acenocoumarol dosage requirements in the group of patients under stable anticoagulation, and to estimate the variability in response to OA."( [The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use].
Kovac, M; Maslać, A; Radojković, D; Rakićević, L, 2009
)
0.64
" To date, several pharmacogenetic-guided dosing algorithms for coumarin derivatives, predominately for warfarin, have been developed."( Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
Barallon, R; Briz, M; Daly, AK; de Boer, A; Haschke-Becher, E; Kamali, F; Kirchheiner, J; Maitland van der Zee, AH; Manolopoulos, VG; Pirmohamed, M; Redekop, WK; Rosendaal, FR; van Schie, RM; Verhoef, TI; Wadelius, MI, 2009
)
0.35
"-1639G>A polymorphism on the acenocoumarol dosage requirements in a group of patients under stable anticoagulation, and to estimate the variability in response to VKA."( The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.
Kovac, MK; Maslac, AR; Radojkovic, DP; Rakicevic, LB, 2010
)
0.65
"-1639G>A, 497C>G, and 1173C>T variants, on acenocoumarol dosage using a novel algorithm approach, in 193 outpatients who had achieved stable anticoagulation."( A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.
Bandrés, F; Calvo, E; Gómez Gallego, F; Lucía, A; Ruiz, JR; Santiago, C; Valle, B; Verde, Z, 2010
)
0.88
"In this observational, pilot study, the efficacy and feasibility of the fixed dose strategy compared to the variable dosing regimen, is investigated."( Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy.
Huisman, W; Khorsand, N; Meijer, K; Muller, M; Overdiek, JW; van Hest, RM; Veeger, NJ, 2011
)
0.37
" Single nucleotide polymorphisms relevant to coumarin derivative dosing on the CYP2C9 and VKORC1 genes were determined."( Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
de Boer, A; le Cessie, S; Maitland-van der Zee, AH; Rosendaal, FR; Schalekamp, T; van der Meer, FJ; van Meegen, E; van Schie, RM; Verhoef, TI; Wessels, JA, 2011
)
0.61
" Dosing is influenced by a variety of acquired factors, while another factor that is associated with the optimal dose is the presence of certain genetic variants."( Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes.
Kovac, MK; Radojkovic, DP; Rakicevic, LB, 2011
)
0.68
" Because some previous studies have shown a dose-response relationship between smoking exposure and the CYP1A2 phenotype, it was also noted that smokers have greater CYP1A2 activity."( A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Becquemont, L; Delavenne, X; Diquet, B; Jaillon, P; Lebot, M; Robert, A; Rousseau, A; Tod, M; Verstuyft, C, 2012
)
0.59
"To develop a population specific pharmacogenetic acenocoumarol dosing algorithm for north Indian patients and show its efficiency in dosage prediction."( Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.
Agarwal, SK; Mittal, B; Mittal, T; Pande, S; Rathore, SS; Singh, SK, 2012
)
0.95
"Multiple and linear stepwise regression analyses were used to include age, sex, height, weight, body surface area, smoking status, VKORC1 -1639 G>A, CYP4F2 1347 G>A, CYP2C9*2,*3 and GGCX 12970 C>G polymorphisms as variables to generate dosing algorithms."( Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.
Agarwal, SK; Mittal, B; Mittal, T; Pande, S; Rathore, SS; Singh, SK, 2012
)
0.69
"The pharmacogenetic dosing algorithm generated by multiple regression analysis explains 41."( Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.
Agarwal, SK; Mittal, B; Mittal, T; Pande, S; Rathore, SS; Singh, SK, 2012
)
0.69
"We have proposed an efficient north India specific pharmacogenetic acenocoumarol dosing algorithm which might become a baseline for personalised medicine approach for treatment of patients in future."( Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.
Agarwal, SK; Mittal, B; Mittal, T; Pande, S; Rathore, SS; Singh, SK, 2012
)
0.93
"Appropriate dosing of coumarins is difficult to establish, due to significant inter-individual variability in the dose required to obtain stable anticoagulation."( An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.
Borobia, AM; Campos, A; Carcas, AJ; Fernández-Capitán, C; Frías, J; Lorenzo, A; Lubomirov, R; Muñoz-Romo, R; Ramírez, E, 2012
)
1
"We have developed a genotyping system to determine the alleles of genes related to interindividual variability in acenocoumarol dosage requirements."( A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism.
Arroyo-Pardo, E; Baeza, C; Borobia, AM; Carcas, AJ; López-Parra, AM, 2013
)
0.82
" The best regression model to predict stable dosage in the Primary Cohort included clinical factors (age and body mass index, BSA) and genetic variants (VKORC1, CYP2C9* and CYP4F2 polymorphisms) and explained up to 50% of stable dose."( Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Antón, AI; Cerezo-Manchado, JJ; Corral, J; Garcia-Barberá, N; González-Conejero, R; Martinez, AB; Pérez-Andreu, V; Roldán, V; Rosafalco, M; Vicente, V, 2013
)
0.65
" The aim of this study is to evaluate the effectiveness and efficiency of an acenocoumarol dosing algorithm developed by our group which includes demographic, clinical and pharmacogenetic variables (VKORC1, CYP2C9, CYP4F2 and ApoE) in patients with venous thromboembolism (VTE)."( Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Abad-Santos, F; Borobia, AM; Carcas, AJ; Díaz, MQ; Fernández-Capitán, C; Madridano, O; Ruiz-Giménez, N; Sillero, PL; Velasco, M, 2012
)
0.87
" Acenocoumarol dose in the control group will be scheduled and adjusted following common clinical practice; in the experimental arm dosing will be following an individualized algorithm developed and validated by our group."( Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Abad-Santos, F; Borobia, AM; Carcas, AJ; Díaz, MQ; Fernández-Capitán, C; Madridano, O; Ruiz-Giménez, N; Sillero, PL; Velasco, M, 2012
)
1.55
"To date, there are no clinical trials comparing pharmacogenetic acenocoumarol dosing algorithm versus routine clinical practice in VTE."( Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Abad-Santos, F; Borobia, AM; Carcas, AJ; Díaz, MQ; Fernández-Capitán, C; Madridano, O; Ruiz-Giménez, N; Sillero, PL; Velasco, M, 2012
)
0.88
" Because there is a large inter-individual and intra-individual variability in dose-response and a small therapeutic window, treatment with coumarin derivatives is challenging."( Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
Daly, AK; de Boer, A; Maitland-van der Zee, AH; Redekop, WK; van Schie, RM; Verhoef, TI, 2014
)
0.63
" We developed a dosing calculation algorithm that is, to the best of our knowledge, the first one to assess the effect of such clinical factors as creatinine clearance and dietary vitamin K intake on the AC dose."( Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Bartnik, A; Bilinska, ZT; Koziarek, J; Pogorzelska, H; Szperl, M; Wolkanin-Bartnik, J, 2013
)
0.6
"Inclusion of a variety of genetic and clinical factors in the dosing calculation algorithm allows for precise AC dose estimation in most patients and thus improves the efficacy and safety of the therapy."( Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Bartnik, A; Bilinska, ZT; Koziarek, J; Pogorzelska, H; Szperl, M; Wolkanin-Bartnik, J, 2013
)
0.6
"Observational evidence suggests that the use of a genotype-guided dosing algorithm may increase the effectiveness and safety of acenocoumarol and phenprocoumon therapy."( A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Barallon, R; de Boer, A; Kolovou, G; Kolovou, V; Konstantinides, S; Le Cessie, S; Maitland-van der Zee, AH; Maltezos, E; Manolopoulos, VG; Ragia, G; Redekop, WK; Remkes, M; Rosendaal, FR; Tavridou, A; Tziakas, D; van der Meer, FJ; van Schie, RM; Verhoef, TI; Wadelius, M, 2013
)
0.85
"We conducted two single-blind, randomized trials comparing a genotype-guided dosing algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1 with a dosing algorithm that included only clinical variables, for the initiation of acenocoumarol or phenprocoumon treatment in patients with atrial fibrillation or venous thromboembolism."( A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Barallon, R; de Boer, A; Kolovou, G; Kolovou, V; Konstantinides, S; Le Cessie, S; Maitland-van der Zee, AH; Maltezos, E; Manolopoulos, VG; Ragia, G; Redekop, WK; Remkes, M; Rosendaal, FR; Tavridou, A; Tziakas, D; van der Meer, FJ; van Schie, RM; Verhoef, TI; Wadelius, M, 2013
)
0.83
"6% for patients receiving genotype-guided dosing and 60."( A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Barallon, R; de Boer, A; Kolovou, G; Kolovou, V; Konstantinides, S; Le Cessie, S; Maitland-van der Zee, AH; Maltezos, E; Manolopoulos, VG; Ragia, G; Redekop, WK; Remkes, M; Rosendaal, FR; Tavridou, A; Tziakas, D; van der Meer, FJ; van Schie, RM; Verhoef, TI; Wadelius, M, 2013
)
0.65
"Genotype-guided dosing of acenocoumarol or phenprocoumon did not improve the percentage of time in the therapeutic INR range during the 12 weeks after the initiation of therapy."( A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Barallon, R; de Boer, A; Kolovou, G; Kolovou, V; Konstantinides, S; Le Cessie, S; Maitland-van der Zee, AH; Maltezos, E; Manolopoulos, VG; Ragia, G; Redekop, WK; Remkes, M; Rosendaal, FR; Tavridou, A; Tziakas, D; van der Meer, FJ; van Schie, RM; Verhoef, TI; Wadelius, M, 2013
)
0.95
" ANN increased the percentage of accurately dosed subjects (mean absolute error ≤1 mg/week) by 14."( Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method.
Almedawar, MM; Elhajj, IH; Habib, RH; Isma'eel, HA; Sakr, GE; Zgheib, NK, 2014
)
0.4
"ANN-based pharmacogenetic guidance of acenocoumarol dosing reduces the error in dosing to achieve target INR."( Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method.
Almedawar, MM; Elhajj, IH; Habib, RH; Isma'eel, HA; Sakr, GE; Zgheib, NK, 2014
)
0.67
" CYP4F2 1347 G > A and GGCX 12970 C > G polymorphisms have been used in the pharmacogenetic dosing algorithms of warfarin for Caucasians and Chinese populations."( CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant.
Agarwal, SK; Mittal, B; Mittal, T; Pande, S; Rathore, SS; Singh, SK, 2014
)
0.62
" Binary logistic regression analysis revealed no significant association of any of the genotypes or alleles with the dosing phenotypes for both the SNPs."( CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant.
Agarwal, SK; Mittal, B; Mittal, T; Pande, S; Rathore, SS; Singh, SK, 2014
)
0.62
" The clinical usefulness of genotype-guided dosing of warfarin has been previously assessed in randomized clinical trials that were limited by lack of power and inconsistent results."( Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Brown, DL; Stergiopoulos, K, 2014
)
0.4
"To compare genotype-guided initial dosing of warfarin and its analogues with clinical dosing protocols."( Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Brown, DL; Stergiopoulos, K, 2014
)
0.4
"MEDLINE (inception to December 31, 2013), EMBASE (inception to December 31, 2013), and the Cochrane Library Central Register of Controlled Trials (inception to December 31, 2013) were searched for randomized clinical trials comparing genotype-guided warfarin dosing vs clinical dosing for adults with indications for anticoagulation."( Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Brown, DL; Stergiopoulos, K, 2014
)
0.4
"In 9 trials, 2812 patients were randomized to receive warfarin, acenocoumarol, or phenprocoumon according to a genotype-guided algorithm or a clinical dosing algorithm."( Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Brown, DL; Stergiopoulos, K, 2014
)
0.64
"In this meta-analysis of randomized clinical trials, a genotype-guided dosing strategy did not result in a greater percentage of time that the INR was within the therapeutic range, fewer patients with an INR greater than 4, or a reduction in major bleeding or thromboembolic events compared with clinical dosing algorithms."( Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Brown, DL; Stergiopoulos, K, 2014
)
0.4
"2084+45G>C polymorphisms on acenocoumarol dosage was observed."( Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Awsiuk, M; Branicka, A; Sadowski, J; Undas, A; Wypasek, E, 2014
)
1
"To develop an acenocoumarol (ACN) dosing algorithm for patients with atrial fibrillation or venous thromboembolism, considering the influence on the stable ACN dose of clinical factors and gene polymorphisms, including CYP2C9*2/*3, VKORC1, CYP4F2*3, ABCB1, APOE, CYP2C19*2/*17, and GGCX."( Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Calleja-Hernández, MA; Cañadas-Garre, M; Gutiérrez-Pimentel, MJ; Jiménez-Varo, E, 2014
)
1.08
"The pharmacogenetic dosing algorithm included CYP2C9, VKORC1, and APOE, which explained 56."( Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Calleja-Hernández, MA; Cañadas-Garre, M; Gutiérrez-Pimentel, MJ; Jiménez-Varo, E, 2014
)
0.72
"The variability in the stable ACN dose was better explained by a pharmacogenetic algorithm including clinical and genetic factors (CYP2C9, VKORC1, and APOE) than by a clinical algorithm, providing a more accurate dosage prediction."( Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Calleja-Hernández, MA; Cañadas-Garre, M; Gutiérrez-Pimentel, MJ; Jiménez-Varo, E, 2014
)
0.72
" However, the safe use of coumarin anticoagulants is restricted by a narrow therapeutic window and large interindividual dosing variations."( Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.
Chen, L; Cheng, J; Han, S; Jia, Z; Li, M; Liu, J; Lu, C; Pei, E; Tang, T; Xu, J; Ye, M; Zhang, X; Zuo, K, 2015
)
0.42
"Four electronic databases were searched from January 1, 2000, to March 1, 2014, for randomized controlled trials of patients who received coumarin anticoagulants according to genotype-guided dosing algorithms."( Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.
Chen, L; Cheng, J; Han, S; Jia, Z; Li, M; Liu, J; Lu, C; Pei, E; Tang, T; Xu, J; Ye, M; Zhang, X; Zuo, K, 2015
)
0.42
"This meta-analysis showed that genotype-guided dosing increased the effectiveness and safety of coumarin therapy compared with standard dosing but did not have advantages compared with clinical variables-guided dosing."( Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.
Chen, L; Cheng, J; Han, S; Jia, Z; Li, M; Liu, J; Lu, C; Pei, E; Tang, T; Xu, J; Ye, M; Zhang, X; Zuo, K, 2015
)
0.42
"To investigate the cost-effectiveness of a pharmacogenetic dosing algorithm versus a clinical dosing algorithm for coumarin anticoagulants in The Netherlands."( Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.
de Boer, A; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI, 2015
)
0.42
"A decision-analytic Markov model was used to analyze the cost-effectiveness of pharmacogenetic dosing of phenprocoumon and acenocoumarol versus clinical dosing."( Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.
de Boer, A; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI, 2015
)
0.62
"Pharmacogenetic dosing improves health only slightly when compared with clinical dosing."( Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.
de Boer, A; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI, 2015
)
0.42
"It has not been investigated how much the use of clinical factors in a dosing algorithm improves the percentage of time in therapeutic range (TTR)."( Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
de Boer, A; Le Cessie, S; Maitland-van der Zee, AH; van der Meer, FJ; Verhoef, TI; Zhang, Y, 2015
)
0.69
" Data from the Dutch patients in the EU-PACT trial (comparing the use of a clinical algorithm with and without genetic information) was used for the clinical dosing algorithm."( Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
de Boer, A; Le Cessie, S; Maitland-van der Zee, AH; van der Meer, FJ; Verhoef, TI; Zhang, Y, 2015
)
0.69
"During the weeks 2-12, the clinical dosing algorithm of acenocoumarol (80 patients) led to a higher TTR (74."( Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
de Boer, A; Le Cessie, S; Maitland-van der Zee, AH; van der Meer, FJ; Verhoef, TI; Zhang, Y, 2015
)
0.94
"The use of a clinical dosing algorithm for acenocoumarol seemed to improve the quality of anticoagulation therapy during the treatment of initial 2-12 weeks."( Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
de Boer, A; Le Cessie, S; Maitland-van der Zee, AH; van der Meer, FJ; Verhoef, TI; Zhang, Y, 2015
)
0.95
" Various dosing pharmacogenetic-guided dosing algorithms have been developed, but further work on their external validation is required."( Extrapolation of acenocoumarol pharmacogenetic algorithms.
Calleja-Hernández, MÁ; Cañadas-Garre, M; Garcés-Robles, V; Gutiérrez-Pimentel, MJ; Jiménez-Varo, E, 2015
)
0.76
" EU-PACT and Borobia pharmacogenetic dosing algorithms were the most accurate in our setting and evidenced the best clinical performance."( Extrapolation of acenocoumarol pharmacogenetic algorithms.
Calleja-Hernández, MÁ; Cañadas-Garre, M; Garcés-Robles, V; Gutiérrez-Pimentel, MJ; Jiménez-Varo, E, 2015
)
0.76
"Among the five models studied, the EU-PACT and Borobia pharmacogenetic dosing algorithms demonstrated the best potential for extrapolation."( Extrapolation of acenocoumarol pharmacogenetic algorithms.
Calleja-Hernández, MÁ; Cañadas-Garre, M; Garcés-Robles, V; Gutiérrez-Pimentel, MJ; Jiménez-Varo, E, 2015
)
0.76
"We applied eight already existing acenocoumarol dosing algorithms to Bulgarian patients with low acenocoumarol dose requirements and investigated which of these algorithms would predict most precisely the dose anticoagulant."( Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.
Chilingirova, N; Dimitrova-Karamfilova, A; Goranova, T; Kaneva, R; Mitev, V; Nachev, G; Tzveova, R, 2015
)
2.14
"All applied acenocoumarol dosing algorithms predicted relatively similar doses of coumarin anticoagulant in both patients."( Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.
Chilingirova, N; Dimitrova-Karamfilova, A; Goranova, T; Kaneva, R; Mitev, V; Nachev, G; Tzveova, R, 2015
)
2.24
" Based on current evidence, clinicians should include body weight, along with other established variables when dosing VKA."( Effect of Body Weight on Dose of Vitamin K Antagonists.
Sakaan, S; Sands, CW; Self, TH; Wallace, JL, 2015
)
0.42
" At 72 hours, the corresponding dose was calculated based on INR in the standard care group (SC, N=92), whereas genetic data (VKORC1, CYP2C9 and CYP4F2) were also considered for the genotype-guided dosing (pharmacogenetic) group (PGx, N=87) by using an algorithm previously validated in 2,683 patients."( Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Antón, AI; Cerezo-Manchado, JJ; Corral, J; González-Conejero, R; Padilla, J; Roldán, V; Rosafalco, M; Vicente, V, 2016
)
0.7
" Validation was by comparing actual dosing to algorithm predictions."( Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema, MJ; Brouwers, JR; Rosendaal, FR; van der Meer, FJ, 2016
)
0.43
" Validation was by comparing actual dosing to algorithm predictions."( Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema, MJ; Brouwers, JR; Rosendaal, FR; van der Meer, FJ, 2016
)
0.43
" Improvement of VKA dosing defined as more time in therapeutic range (TTR) can reduce thrombotic disease and bleeding."( Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema, MJ; Brouwers, JR; Rosendaal, FR; van der Meer, FJ, 2016
)
0.43
" The rate of automated dosage proposals increased to 100%."( Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema, MJ; Brouwers, JR; Rosendaal, FR; van der Meer, FJ, 2016
)
0.43
"The BF-N algorithm performs well in real-life settings and increases the rate of automated dosage proposals."( Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema, MJ; Brouwers, JR; Rosendaal, FR; van der Meer, FJ, 2016
)
0.43
" This was a prospective hospital based study in which allele and genotypic frequencies of CYP2C9 gene polymorphisms; 430C>T and 1075A>C and VKORC1 gene polymorphisms; 1639G>A, 9041G>A and 6009C>T in 106 alleles of north Indian patients with valve replacement on acenocoumarol were determined and their effect on acenocoumarol dosing was studied."( High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Ahluwalia, J; Das, R; Hira, JK; Rana, SS; Sehgal, T; Varma, N; Vijayvergiya, R, 2015
)
0.8
"There is a strong association between genetic polymorphisms and the acenocoumarol dosage requirements."( A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population.
Blanco Bañares, MJ; Borobia, AM; Cabeza Barrera, J; Carcas, AJ; Dávila-Fajardo, CL; Díaz-Villamarín, X; Fernández-Capitán, C; Lubomirov, R; Martínez-González, LJ; Perea León, LM; Tong, HY, 2016
)
0.9
"Presence of a mutant allele of VKORC1 (-1639A & 1173T) and CYP2C9 genes increased the odds of requiring a lower mean dosage of acenocoumarol."( Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
Bharath, G; Christopher, R; Kalpana, SR; Manjunath, CN, 2017
)
0.91
" This analysis supports dosing patients with renal impairment in accordance with patients with normal renal function; however, anti-Xa monitoring could be considered to further support safety in selected patients, particularly those with very severe renal impairment."( A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
Abreu, P; Feugère, G; Heissler, J; Jen, F; Ruiz, MT; Woodruff, S, 2016
)
0.43
" In this study, we assessed the effect of CYP4F2 rs2108622, ABCB1, and GGCX polymorphisms on the safety profile and regime dosing of AC in patients with nonvalvular atrial fibrillation."( The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation.
Ananichuk, AV; Kazakov, RE; Rozhkov, AV; Sychev, DA, 2016
)
0.66
" The VKA dosage (mg/day) after statin initiation was compared with the last VKA dosage before the statin was started."( Statin use decreases coagulation in users of vitamin K antagonists.
Biedermann, JS; Bonafacio, SM; Kruip, MJ; Lijfering, WM; van der Meer, FJ; van Rein, N, 2016
)
0.43
"Initiation of statin treatment was associated with an immediate and long-term minor although statistically significant decrease in VKA dosage in both phenprocoumon and acenocoumarol users, which suggests that statins may have anticoagulant properties."( Statin use decreases coagulation in users of vitamin K antagonists.
Biedermann, JS; Bonafacio, SM; Kruip, MJ; Lijfering, WM; van der Meer, FJ; van Rein, N, 2016
)
0.63
"To generate and validate a pharmacogenomic-guided (PG) dosing algorithm for acenocoumarol in the Greek population."( A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.
Kolovou, G; Kolovou, V; Konstantinides, S; Maitland-van der Zee, AH; Maltezos, E; Manolopoulos, VG; Ragia, G; Tavridou, A; Tziakas, D, 2017
)
1.12
"A total of 140 Greek patients participants of the EU-PACT trial for acenocoumarol, a randomized clinical trial that prospectively compared the effect of a PG dosing algorithm with a clinical dosing algorithm on the percentage of time within INR therapeutic range, who reached acenocoumarol stable dose were included in the study."( A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.
Kolovou, G; Kolovou, V; Konstantinides, S; Maitland-van der Zee, AH; Maltezos, E; Manolopoulos, VG; Ragia, G; Tavridou, A; Tziakas, D, 2017
)
1.12
"Ethnic-specific dosing algorithm is suggested for better prediction of acenocoumarol dosage requirements in patients of Greek origin."( A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.
Kolovou, G; Kolovou, V; Konstantinides, S; Maitland-van der Zee, AH; Maltezos, E; Manolopoulos, VG; Ragia, G; Tavridou, A; Tziakas, D, 2017
)
1.12
" The results support the use of genotype-guided dosing for phenprocoumon in patients < 75 years."( Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.
de Boer, A; Le Cessie, S; Maitland-van der Zee, AH; Manolopoulos, VG; van der Meer, FJ; Verhoef, TI; Zhang, Y, 2017
)
0.69
" Objectives To investigate the effect of genotype-guided dosing stratified by age and the potential factors causing a difference."( Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.
de Boer, A; Le Cessie, S; Maitland-van der Zee, AH; Manolopoulos, VG; van der Meer, FJ; Verhoef, TI; Zhang, Y, 2017
)
0.69
"Essentials Prospective studies of pharmacogenetic-guided (PG) coumarin dosing produced varying results."( Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Asselbergs, FW; Baranova, EV; de Boer, A; le Cessie, S; Maitland-van der Zee, AH; Manolopoulos, VG; Ragia, G; Verhoef, TI, 2017
)
0.46
"Background The multicenter, single-blind, randomized EU-PACT trial compared the safety and efficacy of genotype-guided and non-genetic dosing algorithms for acenocoumarol and phenprocoumon in patients with atrial fibrillation or deep vein thrombosis."( Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Asselbergs, FW; Baranova, EV; de Boer, A; le Cessie, S; Maitland-van der Zee, AH; Manolopoulos, VG; Ragia, G; Verhoef, TI, 2017
)
0.65
" Several genotype-based acenocoumarol dosing algorithms have been created to predict ideal doses at the start of anticoagulant therapy."( Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients.
Ananichuk, AV; Kazakov, RE; Rozhkov, AV; Sychev, DA, 2017
)
1.05
"Nine dosing algorithms were selected through a literature search."( Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients.
Ananichuk, AV; Kazakov, RE; Rozhkov, AV; Sychev, DA, 2017
)
0.74
" Further research is required to find the perfect dosing formula of acenocoumarol maintenance doses in Russian patients."( Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients.
Ananichuk, AV; Kazakov, RE; Rozhkov, AV; Sychev, DA, 2017
)
0.98
"To evaluate the influence of two variants of P450 oxidoreductase (POR), rs2868177 and POR*28, on the stable dosage of acenocoumarol."( Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population.
Blanco Bañares, MJ; Borobia, AM; Carcas, AJ; Fernández Capitán, C; Frías, J; Hernández, R; Lubomirov, R; Martínez Ávila, JC; Muñoz, M; Ramírez, E; Tong, HY, 2017
)
0.9
"The POR*28 heterozygote appears to be associated with the stable dose of acenocoumarol, but its clinical contribution to the prediction of the dosing of this drug is minimal."( Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population.
Blanco Bañares, MJ; Borobia, AM; Carcas, AJ; Fernández Capitán, C; Frías, J; Hernández, R; Lubomirov, R; Martínez Ávila, JC; Muñoz, M; Ramírez, E; Tong, HY, 2017
)
0.92
" The pharmacogenetic dosing algorithm involving VKORC1, CYP2C9 diplotypes and age explains 30."( CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Balogh, S; Melegh, B; Nagy, L; Sipeky, C; Varnai, R, 2017
)
0.7
" Genetic polymorphisms account for high VKA dosage variability."( Meta-Analysis of Genotype-Guided Versus Standard Dosing of Vitamin K Antagonists.
Abdalla, A; Ahmed, S; Bachuwa, G; Hassan, M; Haykal, T; Kheiri, B; Osman, M, 2018
)
0.48
"We investigated the impact of non-genetics factors, and single nucleotide polymorphisms (SNPs) in VKORC1, CYP2C9, CYP4F2, and GGCX on acenocoumarol dosage in Moroccan adult's patients, in order to develop an algorithm to predict acenocoumarol dose for Moroccan patients."( Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
Bensaid, M; Bouaiti, EA; Boulahyaoui, H; Elkhazraji, A; Ibrahimi, A; Messaoudi, N; Nahmtchougli, CP; Zahid, H,
)
0.56
" Their narrow therapeutic range and a dosing strategy based on 'a posteriori' algorithms, pose them as an interesting group for prediction modelling research."( Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.
Arbelbide, J; Belloso, WH; Ferreyro, BL; Jáuregui, EG; Orlova, M; Otero, V; Scibona, P; Vázquez, C, 2018
)
0.75
"Essentials A pediatric pharmacogenetic dosing algorithm for acenocoumarol has not yet been developed."( The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.
Appel, IM; Bierings, MB; de Boer, A; le Cessie, S; Maagdenberg, H; Maitland-van der Zee, AH; Swen, JJ; Tamminga, RYJ; van der Meer, FJM; van der Straaten, T; van Ommen, CH, 2018
)
1.08
" For warfarin, pediatric dosing algorithms have been developed to predict the correct dose for a patient; however, this is not the case for acenocoumarol."( The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.
Appel, IM; Bierings, MB; de Boer, A; le Cessie, S; Maagdenberg, H; Maitland-van der Zee, AH; Swen, JJ; Tamminga, RYJ; van der Meer, FJM; van der Straaten, T; van Ommen, CH, 2018
)
1.04
" hospitals, primary care doctor or even by the patient itself) and can aid in dosage management."( Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma.
Estevez, MC; Lechuga, LM; Marco, MP; Peláez, EC; Portela, A; Salvador, JP, 2018
)
0.73
" Therefore, more precise dosing with smaller dose increments might improve quality of VKA treatment in the elderly."( More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study.
Kooistra, HAM; Meijer, K; Piersma-Wichers, M; van Miert, JHA; Veeger, NJGM, 2020
)
0.87
"7 in the precise dosing group versus 67."( More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study.
Kooistra, HAM; Meijer, K; Piersma-Wichers, M; van Miert, JHA; Veeger, NJGM, 2020
)
0.87
"Although more precise dosing of acenocoumarol leads to a slightly higher TTR, this effect is too small to convey a relevant clinical benefit and could be abolished by the increased risk of medication errors."( More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study.
Kooistra, HAM; Meijer, K; Piersma-Wichers, M; van Miert, JHA; Veeger, NJGM, 2020
)
1.15
" In this context, these studies are relevant for drugs such as acenocoumarol, whose dosage must be controlled due to, among other factors, food-drug interactions."( Biomodification of acenocoumarol by bifidobacteria.
Assad, S; Fragomeno, M; Minnaard, J; Mobili, P; Pérez, PF; Peruzzo, PJ, 2021
)
1.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anticoagulantAn agent that prevents blood clotting.
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitorAn EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor that interferes with the action of NAD(P)H dehydrogenase (quinone), EC 1.6.5.2.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
methyl ketoneA ketone of formula RC(=O)CH3 (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Acenocoumarol Action Pathway203
Effect of intestinal microbiome on anticoagulant response of vitamin K antagonists413

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency100.00000.003245.467312,589.2998AID2517
LuciferasePhotinus pyralis (common eastern firefly)Potency30.13130.007215.758889.3584AID588342
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521; AID1159523
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.57670.000817.505159.3239AID1159531
GVesicular stomatitis virusPotency2.18760.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency11.45540.001019.414170.9645AID743094
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.07950.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency37.57800.001628.015177.1139AID1259385
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency44.66843.548119.542744.6684AID743266
gemininHomo sapiens (human)Potency0.25930.004611.374133.4983AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency17.78280.00419.962528.1838AID2675
Interferon betaHomo sapiens (human)Potency1.83740.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
Guanine nucleotide-binding protein GHomo sapiens (human)Potency22.38721.995325.532750.1187AID624288
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (93)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID419495Volume of distribution at steady state in human at 25 mg, iv2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID80631Percent relaxation of isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID411793Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID80624Percent relaxation using isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID419496Protein binding in human plasma at 25 mg, iv2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID293981Inhibition of rat microsomal VKER2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis and structure-activity relationships of novel warfarin derivatives.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346079Rat vitamin K epoxide reductase complex subunit 1 (1.-.-.- Oxidoreductases)2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis and structure-activity relationships of novel warfarin derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,256)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990419 (33.36)18.7374
1990's161 (12.82)18.2507
2000's319 (25.40)29.6817
2010's316 (25.16)24.3611
2020's41 (3.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.06 (24.57)
Research Supply Index7.35 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index136.42 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (76.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials159 (11.44%)5.53%
Reviews58 (4.17%)6.00%
Case Studies371 (26.69%)4.05%
Observational23 (1.65%)0.25%
Other779 (56.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF) [NCT02942576]Phase 3632 participants (Actual)Interventional2017-03-21Completed
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism [NCT01164046]Phase 356 participants (Actual)Interventional2010-08-31Terminated(stopped due to Due to slow inclusion of patients)
Rivaroxaban Plus Aspirin Versus Acenocoumarol to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation With Rivaroxaban [NCT05515120]Phase 2/Phase 358 participants (Actual)Interventional2021-01-03Completed
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension : HEMA-HTP Multicentric Study. [NCT02800941]203 participants (Anticipated)Observational2017-07-05Recruiting
Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation [NCT01141153]Phase 4304 participants (Anticipated)Interventional2010-06-30Active, not recruiting
A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patie [NCT00742859]Phase 2508 participants (Actual)Interventional2008-10-31Completed
Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study [NCT00966290]Phase 41,006 participants (Actual)Interventional2003-02-28Completed
Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography [NCT02826200]Phase 4200 participants (Anticipated)Interventional2016-07-31Recruiting
Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY) [NCT02742480]500 participants (Anticipated)Observational2016-06-28Recruiting
Burden of Ischemic Stroke and Adherence to Oral Anticoagulants in Atrial Fibrillation in the UK Primary Care [NCT04099238]3,739 participants (Actual)Observational2019-10-01Completed
The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in [NCT00062803]Phase 30 participants Interventional2003-06-30Completed
Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism [NCT00711308]Phase 4102 participants (Actual)Interventional2005-04-30Completed
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Non Valvular Atrial Fibrillation in Patients Aged 80 Years and Over, Living at Home or in Nursing Home. A Prospective Cohort Study [NCT02286414]159 participants (Actual)Observational2015-02-28Completed
Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD [NCT02046460]Phase 4194 participants (Actual)Interventional2013-09-30Completed
Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis [NCT00689520]Phase 4241 participants (Actual)Interventional2002-01-31Completed
A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY [NCT01851824]Phase 19 participants (Actual)Interventional2013-08-31Completed
Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers [NCT00512928]20 participants (Actual)Interventional2007-09-30Completed
Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage [NCT03153150]Phase 3203 participants (Actual)Interventional2018-03-28Completed
The AMADEUS Trial, A Multicenter, Randomized, Open-label, Assessor Blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Idraparinux (SR34006) With Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboe [NCT00070655]Phase 34,673 participants (Actual)Interventional2003-09-30Completed
[NCT01631877]0 participants (Actual)Interventional2012-06-30Withdrawn(stopped due to lack of funds)
Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients [NCT01727427]695 participants (Actual)Observational2012-11-30Completed
Creation and Validation of a Pharmacogenetic Dosage Algorithm for Acenocoumarol in Patients With Venous Thromboembolic Disease, Atrial Fibrillation and/or Mechanical Valvular Heart Prosthesis [NCT03015025]340 participants (Actual)Observational2011-10-31Completed
Left Ventricular Thrombus Formation After Acute Myocardial Infarction - a Randomized Multi-center Trial Comparing Two Different Anti-thrombotic Regimens [NCT01556659]250 participants (Anticipated)Interventional2012-03-31Recruiting
English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria. [NCT02273609]1,524 participants (Actual)Observational2014-02-28Completed
Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care [NCT03154489]204 participants (Actual)Interventional2017-05-22Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00742859 (2) [back to overview]Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)
NCT00742859 (2) [back to overview]Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode
NCT02942576 (4) [back to overview]Number of Participants Who Experienced Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH]) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)
NCT02942576 (4) [back to overview]Number of Participants Who Experienced the Composite of All-cause Death, Stroke (Alternative), and Major Bleeding (ISTH) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)
NCT02942576 (4) [back to overview]Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data)
NCT02942576 (4) [back to overview]Number of Participants Who Experienced the Composite of Stroke (VARC-2), Systemic Embolic Events (SEE), and Cardiovascular (CV) Mortality in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)

The time to the first occurrence of any bleeding event. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution. (NCT00742859)
Timeframe: A maximum of 1 year

InterventionNumber of Patients per 100 Patient years (Number)
Betrixaban 40 mg50.5
Betrixaban 60 mg77.9
Betrixaban 80 mg56.0
Warfarin103

[back to top]

Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode

The primary endpoint is the time to the first occurrence of major or clinically relevant non-major bleeding. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution. (NCT00742859)
Timeframe: A maximum of 1 year

InterventionNumber of Patients per 100 Patient years (Number)
Betrixaban 40 mg2.02
Betrixaban 60 mg10.1
Betrixaban 80 mg10.5
Warfarin14.6

[back to top]

Number of Participants Who Experienced Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH]) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability. (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen10
VKA-based Regimen3

[back to top]

Number of Participants Who Experienced the Composite of All-cause Death, Stroke (Alternative), and Major Bleeding (ISTH) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

"An alternative definition characterized stroke (ischemic, hemorrhagic, or undetermined) as an abrupt onset, over minutes to hours, of a focal neurological deficit in the distribution of a single brain artery that was not due to an identifiable nonvascular cause (ie, brain tumor or trauma), and that either lasted at least 24 hours or resulted in death within 24 hours of onset.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen2

[back to top]

Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data)

"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen2

[back to top]

Number of Participants Who Experienced the Composite of Stroke (VARC-2), Systemic Embolic Events (SEE), and Cardiovascular (CV) Mortality in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~SEE was defined as an arterial embolism resulting in clinical ischemia, excluding the central nervous system, coronary, and pulmonary arterial circulation.~CV mortality was defined as cardiac or vascular death according to Academic Research Consortium." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen0

[back to top]